Should I buy or sell Inozyme Pharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INZY shares. View INZY analyst ratings or view top-rated stocks .

What is Inozyme Pharma's stock price target for 2024?

4 equities research analysts have issued 12-month target prices for Inozyme Pharma's shares. Their INZY share price targets range from $14.00 to $23.00. On average, they anticipate the company's share price to reach $17.00 in the next year. This suggests a possible upside of 276.9% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts .

How have INZY shares performed in 2024?

Inozyme Pharma's stock was trading at $4.26 at the start of the year. Since then, INZY stock has increased by 5.9% and is now trading at $4.51. View the best growth stocks for 2024 here .

Are investors shorting Inozyme Pharma?

Inozyme Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,580,000 shares, an increase of 8.4% from the March 15th total of 2,380,000 shares. Based on an average daily trading volume, of 611,300 shares, the days-to-cover ratio is currently 4.2 days. Currently, 6.3% of the shares of the stock are short sold. View Inozyme Pharma's Short Interest .

When is Inozyme Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INZY earnings forecast .

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG) , RTX (RTX) , Cisco Systems (CSCO) , CSX (CSX) , CVS Health (CVS) , Home Depot (HD) , Resideo Technologies (REZI) , Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT) .

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:INZY

Inozyme Pharma (INZY) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free INZY Stock Alerts

$4.51

-0.07 (-1.53%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.38
▼
$4.63
50-Day Range: $4.58
▼
$7.66
52-Week Range: $2.69
▼
$7.80

Volume: 591,071 shs
Average Volume: 616,108 shs
Market Capitalization: $278.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get Inozyme Pharma alerts:

Inozyme Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 276.9% Upside
$17.00 Price Target
Short Interest: Bearish
6.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$52,210 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.46) to ($1.58) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.02 out of 5 stars

Medical Sector

565th out of 911 stocks

Pharmaceutical Preparations Industry

251st out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Inozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Inozyme Pharma has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.27% of the float of Inozyme Pharma has been sold short.
Short Interest Ratio / Days to Cover
Inozyme Pharma has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Inozyme Pharma has recently increased by 8.40%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Inozyme Pharma does not currently pay a dividend.
Dividend Growth
Inozyme Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INZY.

3.3

News and Social Media Coverage

News Sentiment
Inozyme Pharma has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.
Search Interest
Only 8 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inozyme Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,210.00 in company stock.
Percentage Held by Insiders
11.88% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.46) to ($1.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inozyme Pharma is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inozyme Pharma is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inozyme Pharma has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Inozyme Pharma Stock (NASDAQ:INZY)

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

INZY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INZY Stock News Headlines

April 4, 2024 | insidertrades.com

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

April 16, 2024 | americanbankingnews.com

Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 10, 2024 | americanbankingnews.com

Inozyme Pharma (NASDAQ:INZY) Given Buy Rating at Needham & Company LLC

April 10, 2024 | americanbankingnews.com

Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $14.00 by Analysts at Bank of America

April 9, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)

April 8, 2024 | markets.businessinsider.com

Inozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock Up

April 8, 2024 | globenewswire.com

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 5, 2024 | globenewswire.com

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2024 | globenewswire.com

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

March 26, 2024 | globenewswire.com

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

March 13, 2024 | markets.businessinsider.com

Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701

March 12, 2024 | benzinga.com

Inozyme Pharma: Q4 Earnings Insights

March 12, 2024 | benzinga.com

Inozyme Pharma: Q4 Earnings Insights

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidence

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidence

March 12, 2024 | markets.businessinsider.com

Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation

March 12, 2024 | finanznachrichten.de

Inozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

March 12, 2024 | globenewswire.com

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

February 26, 2024 | globenewswire.com

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

February 25, 2024 | finance.yahoo.com

INZY May 2024 5.000 put

February 24, 2024 | benzinga.com

Inozyme Pharma Stock (NASDAQ:INZY), Short Interest Report

February 22, 2024 | benzinga.com

Bakker Juliet Tammenoms's Net Worth

January 30, 2024 | finance.yahoo.com

Inozyme Pharma, Inc. (INZY)

January 19, 2024 | morningstar.com

Inozyme Pharma Inc Ordinary Shares INZY

December 21, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

See More Headlines

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:INZY
CUSIP: N/A
CIK: 1693011
Web: www.inozyme.com
Phone: 857-330-4340
Fax: N/A
Employees: 59
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $23.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +276.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.86%
Return on Assets: -40.71%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 13.36
Quick Ratio: 13.36

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.27 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 61,770,000
Free Float: 54,433,000
Market Cap: $278.58 million
Optionable: Optionable
Beta: 1.37

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Douglas A. Treco Ph.D. (Age 66)
CEO & Chairman
Comp: $77k
Mr. Axel Bolte M.B.A. (Age 52)
M.Sc., Co-Founder, Senior Advisor & Director
Comp: $1.03M
Mr. Sanjay S. Subramanian M.B.A. (Age 47)
M.S., Senior VP, CFO & Principal Accounting Officer
Comp: $726.3k
Dr. Demetrios Braddock M.D.
Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Dr. Matthew Winton Ph.D. (Age 46)
Senior VP & COO
Dr. Soojin Kim Ph.D.
Senior VP & Chief Technical Operations Officer
Dr. David Thompson M.A.
M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development Officer
Mr. Stefan Riley
Director of Investor Relations
Ms. Gayle Gironda
Senior VP & Chief People Officer
Dr. Yves Sabbagh Ph.D.
Chairman of Scientific Advisory Board & Senior VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INZY Stock Analysis - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INZY shares.
View INZY analyst ratings or view top-rated stocks.
What is Inozyme Pharma's stock price target for 2024?: 4 equities research analysts have issued 12-month target prices for Inozyme Pharma's shares. Their INZY share price targets range from $14.00 to $23.00. On average, they anticipate the company's share price to reach $17.00 in the next year. This suggests a possible upside of 276.9% from the stock's current price.
View analysts price targets for INZY or view top-rated stocks among Wall Street analysts.
How have INZY shares performed in 2024?: Inozyme Pharma's stock was trading at $4.26 at the start of the year. Since then, INZY stock has increased by 5.9% and is now trading at $4.51.
View the best growth stocks for 2024 here.
Are investors shorting Inozyme Pharma?: Inozyme Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,580,000 shares, an increase of 8.4% from the March 15th total of 2,380,000 shares. Based on an average daily trading volume, of 611,300 shares, the days-to-cover ratio is currently 4.2 days. Currently, 6.3% of the shares of the stock are short sold.
View Inozyme Pharma's Short Interest.
When is Inozyme Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our INZY earnings forecast.

How were Inozyme Pharma's earnings last quarter?: Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04.
What other stocks do shareholders of Inozyme Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).
When did Inozyme Pharma IPO?: Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Inozyme Pharma?: Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INZY) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inozyme Pharma (INZY) Stock Price, News & Analysis

Inozyme Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inozyme Pharma Stock (NASDAQ:INZY)

INZY Stock Price History

INZY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

INZY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™